Resources Repository
-
ReviewPublication 2008Modeling Cervical Cancer Prevention in Developed Countries
Decision-analytic models are increasingly developed to simulate disease burden and interventions in different settings in …
Decision-analytic models are increasingly developed to simulate disease burden and interventions in different settings in order to evaluate the benefits and cost-effectiveness of primary and secondary interventions. This article is a review of mathematical models that have been used to evaluate HPV vaccination in the context of developed countries with existing screening programs. Despite variations in model assumptions and uncertainty in existing data, pre-adolescent vaccination of females in the setting of current screening practices has…
Microsimulation | Mathematical Models | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | State-Transition | Dynamic Transmission | Science/Technology -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Microsimulation | Mathematical Models | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Science/Technology | Asia & Pacific -
ArticlePublication 2008Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries
This paper presents an empirically calibrated mathematical model of gastric cancer and H. pylori in …
This paper presents an empirically calibrated mathematical model of gastric cancer and H. pylori in China and Colombia to provide qualitative insight into the cost-effectiveness of gastric cancer prevention strategies. Despite studies that have established the relationship between Helicobacter pylori and gastric cancer and H. pylori treatment reducing cancer incidence among individuals without preexisting precancerous lesions, screening for H. pylori is still being debated. The authors synthesized…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Microsimulation | Mathematical Models | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2007Multiparameter Calibration of a Natural History Model of Cervical Cancer
This paper presents a two-step approach to model calibration of a comprehensive natural history model …
This paper presents a two-step approach to model calibration of a comprehensive natural history model of human papillomavirus (HPV) and cervical cancer. Using primary epidemiologic data from a longitudinal study of women in Brazil, a plausible range for each input parameter was identified that would produce model output within the 95% confidence intervals of the data. The authors then performed a simultaneous search over all input parameters to identify parameter sets that produced output consistent…
Microsimulation | Mathematical Models | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Latin America & Caribbean -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Microsimulation | Decision Analysis | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Cost-Effectiveness Analysis | North America -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Microsimulation | Test Performance | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | State-Transition | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Global | North America -
ReportPublication 2016Modeling to Inform Strategies to Improve Population Health
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential …
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential uses of simulation and other types of modeling for improving health. Participants worked to identify how modeling could inform population health decision making (selecting and refining potential strategies, ranging from interventions to investments) based on lessons learned from models that have been, or have not been, used successfully, opportunities and barriers to incorporating models into decision making, and data needs and…
Dynamic Simulation | Microsimulation | Mathematical Models | Decision Analysis | Health/Medicine | Chronic Disease/Risk | State-Transition | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Government/Law | North America -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Mathematical Models | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Global | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Microsimulation | Calibration/Validation | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Cost-Effectiveness Analysis | Clinical Care | Economics/Finance | Science/Technology | Sub-Saharan Africa